chrisvoncsefalvay/vaers-outcomes huggingface dataset:
18JUL92 resp distress, urticaria to ER; 21JUL92 adm to hosp given EPI, DPH & Pred; WBC 16; MD states pt had anaphylatic reaction to Hep vax;
The patient stated that the most recent vaccine she received was Shingrix from her primary pharmacy in March.  She requested the RSV (Arexvy) vaccine.  She was then immunized.  The claim for the vaccination rejected by the patient's primary insurance.  The insurance company informed us that the patient had received Abrysbo on October 19, 2023 at her primary pharmacy.  Upon calling the patient, she informed us that she had no recollection of receiving a vaccination for anything when she went to her pharmacy on that day.  She did remember being told that she was not yet due for her second dose of the Shingrix vaccine, but seemed quite sure she had not received any vaccinations that day.  I called the pharmacy that had provided the vaccination, and the pharmacist verified that the vaccine had been administered.  I then called the patient's primary care physician and explained the situation.  The doctor's nurse returned my call and stated she would inform the prescriber.
Left side headache; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration on 07Apr2021 at 12:00 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient was not allergic to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021, the patient experienced left side headache. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left side headache was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Husband called to report to Director Division of Health Protection, that patient received LAIV IN and that she is in first trimester of pregancy.  Requested records and requested that HD consult with patients obstetrician.  No symptoms or adverse reactions reported at this time.  11/2/09:  OB/GYN records received for dates of service 11/2/09.  Dx:  Pregnant pt. received LAIV H1N1 Flu Vaccine at 5 weeks gestation. Assessment:  As above.  Plan:  1.  US done on date of service, confirmed twin pregnancy.  2.  Consultation planned with medical geneticist to discuss teratogenicity. 3.  US of fetal anatomy at 20 weeks gestation 4.  Potential fetal echocardiogram performed by pediatric             cardiologist at 20 weeks IF any information becomes available that the H1N1 influenza vaccination is associated with congenital cardiac abnormalities.  5.  The patient was counseled on her ability to terminate her pregnancy for any reason up to 20 weeks.   ICD 9 Code:  655.33.
pt recvd vax 12MAY92 & severe screaming spells started @ 12noon-same day terminated @ 430AM on 13MAY93;
pt recv vax;devel high fever,morbilliform rash,conjunctivitis&koplick spots 1 wk p/ MMR;
Information has been received from a certified medical assistant referring to unspecified numbers of patients of unknown age and gender. There was no information about the patients' medical history and concurrent condition. On unknown dates these patients were vaccinated with improperly stored ROTATEQ (lot # L008574, expiration date: 22-NOV-2016, strength and dose unknown) orally (incorrect product storage). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Pt states she started having a really high fever, feeling sick, reports severe swelling and redness in the arm at injection site
This spontaneous report was received from a pharmacist regarding a 50 year old female patient. The patient's medical history, concurrent conditions, drug allergies or concomitant medications were not reported. On an unspecified date in February 2017, the patient might have been vaccinated with a dose of RECOMBIVAX HB 10/1.0 microgram/ml injection, pediatric formulation (dose, lot number and expiration date were not provided) for prophylaxis. In March 2017, (reported as "approximately one month later"),  the patient received an adult dose of RECOMBIVAX HB 10/1.0 microgram/ml injection, (dose was not reported) (lot number: M039201; expiration date: 04-NOV-2018) for prophylaxis. No adverse effects were reported. Additional information is not expected as the reporter refused additional contact.
Patient reported itching face and spots on face within 30 minutes of vaccination.  No SOB or other symptoms.  Patient felt better after resting and was released to home.
second dose was administered more than 42 days after first dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was administered more than 42 days after first dose) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was administered more than 42 days after first dose). On 02-Aug-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was administered more than 42 days after first dose) had resolved.            Other concomitant medications include supplements and vitamins.  No treatment medications were provided by the reporter.
looked as if he was seizing post vaccination.  was not responding as we moved him to the floor and called 911.  eyes rolled back and upper body shaking. resolved on his owe and was able to speak to us and sit up.  asked him to wait for paramedics to clear him before he moves.  paramedics took vitals and thought it might just be him fainting although pharmacist and sister saw him shaking.  he was taken by ambulance to nearby hospital
Head started feeling real stuffy, took a DAYQUIL about 15 mins after the palms of hands started itching and burning. Within mins it had spread to all my body. Took a cold shower but still kept itching. Went to firehall, they called hospital, went to hospital and they gave BENADRYL.
Patient had requested a split dose of the 2nd Moderna vaccine due to prior history of having shingles soon after 1st dose.  Received 0.05ml at ~3pm.  Around 3.12 or 3.18pm he began to complain of L eye blurred vision.  Pt was evaluated and noted to have no other headaches, dizziness, SOB, chest pain.  He reported that R eye vision was okay.  Unable to read first line of snellen eye chart with left eye.  Visual fields were intact, EOMI, and PERRL.  He denies a shade being pulled over his eye. Pt was taken to the ED where vital signs were stable.  A brief check showed stable blood pressure and blood glucose.  Pt then eloped from the ED and went to another hospital's ED.  There he was found to have a left central retinal artery occlusion.
Child present for immunization clinic with her family.  Following administration of IPV and Hep A vaccinations, she experienced a syncopal episode.  Child was seated at the table and was caught by parent and RN as she fainted.  Child quickly began to rouse from syncopal episode, parent picked her up and then sat with her on a row of chairs so child?s head could be lowered and feet elevated above her heart.  VS taken while laying down-BP 110/70, HR 68 and RR 18.  After a few minutes, client reported feeling nauseous and requested to sit upright.  Once seated, she was able to take some sips of water.  Parent reported child had last eaten at lunch time.  Nausea subsided, and child continued to sip water and reported a slight headache.  Parents requested for child to receive Varicella vaccination after syncopal incident.  Following administration of final vaccination, client able to ambulate independently to the Public Health lobby space where family remained for an additional 10 minutes for parents and staff to observe child for any effect from additional vaccination.
First day arm pain  shoulder and a bit chest pain. Gun pain too. Next day still arm pain.
nausea PT felt better after she was given fluids orally and something to eat and to lie down  no evidence of anaphylaxis; pt was watched for 15-20min post vacccination; she was discharge  instruction to eat breakfast and rtn if n/v or abd pain, fever or sob , cough or chest pain-DR VU
Began feeling lymph nodes in neck swell.  Later felt tired.  At bedtime, noticed L eye and R upper lip were swollen.  Took Benadryl at bedtime, awoke without any symptoms.
yeast infection in mouth; This is a spontaneous report from a contactable healthcare professional (HCP). This HCP reported about a female patient of an unspecified age who received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration as single dose for COVID-19 immunization. The patient's medical history and concomitant were not reported. On an unspecified date, the patient experienced yeast infection in mouth. The clinical outcome of the yeast infection in mouth was unknown.  The lot number for the vaccine, BNT162b2, was not provided and will be requested during follow-up.
Information has been received from a patient with no pertinent medical history and no drug reactions/allergies who on 30-OCT-2007 was vaccinated with a 0.65 mL dose of ZOSTAVAX (Oka/Merck).  There was no concomitant medication.  On 30-OCT-2007 the patient experienced feeling stronger and more stimulated.  There were no lab diagnostics studies performed.  The outcome is reported as not recovered. No medical attention was sought.  There was no product quality complaint.  Additional information has been requested.
This spontaneous report was received from a nurse concerning an unspecified patient of unknown age and gender. On an unknown date the patient was vaccinated with improperly stored ROTATEQ Lot number was reported as: K010221, expiration date; 12-MAY-2016, oral. Concomitant medications were not reported. No adverse effects were reported and there was no product quality complaint involved. Follow up information has been received from the reporting nurse on 09-MAR-2015, who was available to provide the lot number and expiration date of the vaccine. The reporter also stated that the patient identification information was not available at the time of the call. This is one of several reports received from the same reporter. Additional information has been requested.
Hi I have got twice severe allergy after covid shot; vomit every 2 min; hives all over and inside mouth; high bp; chest pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALLERGY TO VACCINE (non-serious), outcome "unknown", described as "Hi I have got twice severe allergy after covid shot "; VOMITING (non-serious), outcome "unknown", described as "vomit every 2 min"; URTICARIA (non-serious), outcome "unknown", described as "hives all over and inside mouth"; HYPERTENSION (non-serious), outcome "recovered", described as "high bp"; CHEST PAIN (non-serious), outcome "recovered", described as "chest pain". Relevant laboratory tests and procedures are available in the appropriate section.  The lot number for bnt162b2 was not provided and will be requested during follow up.
I ended up starting my period April 20, 2020 (same day I got the vaccine) and it was the heaviest cycle I've had in years. I went through several tampons in a day for about a week til my period abruptly stopped on April 26, 2020.  It started about 2 hours after the vaccination. I usually don't cramp but I was having problems sleeping because of how bad it got. I was also more bloated than my usual cycles. I dealt with extreme fatigue, I slept a lot that week and I did the bare minimum that week at work (which is unusual for me).  I also don't usually have mood swings but I felt like my hormones were a bit intense to the point I kept snapping at people even though I like to think of myself as level-headed.
given one pediatric dose of Engerix-B / (0.5ML); given one pediatric dose of Engerix-B; This case was reported by a nurse via call center representative and described the occurrence of underdose in a 42-year-old female patient who received HBV (Engerix B pediatric) (batch number 73H93, expiry date 10th January 2022) for prophylaxis.   On 13th July 2021, the patient received Engerix B pediatric .5 ml. On 13th July 2021, unknown after receiving Engerix B pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown.  Additional details were reported as follows: The reporter drawn a titer, that an adult was given one pediatric dose of Engerix-B as a booster dose, which led to underdose and adult use of a child product. The reporter consented to follow up.
Moderately rapid heart rate when at rest, that would occur occasionally throughout the day generally resolving itself in approximately 1/2 an hour. Dizzy sensation and felt pressure ie could feel my heart beat in my neck. This symptom persists but seems to have lessen in frequency.
Pain in arm; Chills; Fever; Not feeling well; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP6955), via an unspecified route of administration in the right arm on 25Mar2021 at 00:30 (at the age of 52-year-old), as DOSE 1, single for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. Medical history included thyroid Thyroid cancer but had no allergies to any medicines, food or other products. Concomitant medications included influenza virus vaccine(flu). On unknown date, the patient experienced pain in the arm. On day 4, 29Mar2021, the patient experienced chills, fever and was not feeling well in the whole body. The patient had received no treatment for the clinical events. The clinical outcome of the events pain in arm was recovered on an unknown date; chills, fever and not feeling well was recovered on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: Updated country added in patient tab; updated relevant Med History and narrative tab per source provided; updated vaccination Facility Type and Vaccination Facility Country; updated Onset Date/Time for events updated Leading and final sentence.
Pain in right shoulder which started about 12 hours after injection.  A month later it's still very painful, no remission.
Diarrhea, off colored stools, screaming, moaning, groaning, knees to chest, twitching, constant unhappy movements, sweaty from pain, tossing while trying to sleep, jumpy while feeding, not feeding regularly.
This spontaneous report was received from a medical assistant concerning multiple unspecified patients of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not reported. On unspecified dates, the patient were vaccinated with improperly stored doses of ROTATEQ 1 dose, orally, lot # M038209, expiration date: 23-APR-2018, as prophylaxis (Strength was not reported), which experienced a temperature excursion between 0 to 1 Celsius degrees for 59 hours and 30 minutes. There were no previous temperature excursions reported. Data logger was not involved. No adverse effects were reported. Additional information has been requested.
acute pain in hip area, began suddenly and woke me up following morning after second shot has persisted for the last 6 days(and is still painful when walking though not quite as badly as it was.
Initial information received on 12-Nov-2018 regarding an unsolicited valid non-serious case received from a consumer/non-health care professional. This case is linked with 2018SA315703 and 2018SA315692 (same reporter). This case involves a 12 years old male patient who received a 0.5 mL dose of suspect FLUBLOK QIV (lot number: QSAA1804 and expiry date: 01-Jun-2019) via intramuscular route in the right deltoid on 12-Nov-2018. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided. t was a case of actual medication error due to inappropriate age at vaccine administration. The patient received a FLUBLOCK QUADRIVALENT in his left deltoid who is under the age of 18. There were no side effects. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. List of documents held by sender: none.
she hadn't eaten anything since the night before; felt dizzy; a little more fatigued than usual; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 52 year-old female patient received bnt162b2 (BNT162B2), administration date 05Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "allergic to sulfa" (unspecified if ongoing), notes: allergic to sulfa; "she has arthritis on her knee" (unspecified if ongoing), notes: takes a steroid injection. The patient's concomitant medications were not reported. Past drug history included: Steroid injection for arthritis on knee. The following information was reported: DECREASED APPETITE (non-serious) with onset Mar2021, outcome "unknown", described as "she hadn't eaten anything since the night before"; DIZZINESS (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "felt dizzy"; FATIGUE (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "a little more fatigued than usual". Therapeutic measures were taken as a result of dizziness.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Metal taste in his mouth; Smelling bacon; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 14 year-old male patient received bnt162b2 (BNT162B2), administered in arm, administration date 13May2021 21:00 (Batch/Lot number: unknown) at the age of 14 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "ADHD" (unspecified if ongoing); "Anxiety" (unspecified if ongoing). Concomitant medication(s) included: DEXMETHYLPHENIDATE (ongoing); SERTRALINE HYDROCHLORIDE (ongoing). The following information was reported: DYSGEUSIA (non-serious) with onset 14May2021 11:18, outcome "unknown", described as "Metal taste in his mouth"; PAROSMIA (non-serious) with onset 14May2021, outcome "not recovered", described as "Smelling bacon". It was unknown if therapeutic measures were taken as a result of parosmia.  Additional information: Reporter is calling about Pfizer covid vaccine. Reporter is calling about her son. Reporter's son is the patient. Reporter states that patient is a hypochondriac. Patient just texted reporter from school. Patient smells bacon, and has a metal taste in his mouth. Reporter thinks that this could be in patient's head. Reporter is asking if other people have experienced this .Patient smells bacon, and has a metal taste in his mouth: Patient received the vaccine late last night, about 21:00. Patient is experiencing symptoms today while at school. Patient is at lunch. Reporter states that patient would probably say that it has gotten worse. At first patient smelled bacon, and then he got a metal taste in his mouth. Reporter thinks that it is all in patients head.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Participant of the vaccine Trumenba is vaccinated on 4/27/17 10:30am in left deltoid area. Mother returns to immunization clinic on 4/28/17 10:00am because today at 8:00am the child was taken to urgent care for redness on left deltoid area, in area where vaccination was administered on 4/27/17. She handed the CBC and I saw the arm red and swollen, mother states that the labs were ok and that it could be a cellulitis. The Dr at the urgent care states it could be cellulitis and prescribed Acetaminophen 1g PO. They bring child to the clinic, I checked the arm and it was red in left deltoid area and warm to touch, cold ice compress was given and PANADOL 1g PO.
I experienced after my J&J vaccine, had a uterine ablation May of last year. I had severe severe vaginal bleeding, had to go to the doctor and receive an ultrasound.   I have had my menstrual cycle, with oain.
Rash at the injection site two weeks after receiving the Moderna COVID-19 Vaccine; Swelling at the injection site two weeks after receiving the Moderna COVID-19 Vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE RASH (Rash at the injection site two weeks after receiving the Moderna COVID-19 Vaccine) and VACCINATION SITE SWELLING (Swelling at the injection site two weeks after receiving the Moderna COVID-19 Vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history provided.).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2021, the patient experienced VACCINATION SITE RASH (Rash at the injection site two weeks after receiving the Moderna COVID-19 Vaccine) and VACCINATION SITE SWELLING (Swelling at the injection site two weeks after receiving the Moderna COVID-19 Vaccine). At the time of the report, VACCINATION SITE RASH (Rash at the injection site two weeks after receiving the Moderna COVID-19 Vaccine) and VACCINATION SITE SWELLING (Swelling at the injection site two weeks after receiving the Moderna COVID-19 Vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment and concomitant medications were not provided by reporter.   Reporter did not allow further contact